Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
60505-4534-02 60505-4534 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4535-01 60505-4535 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4535-02 60505-4535 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
60505-4537-01 60505-4537 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 March 8, 2023 In Use
60505-4537-02 60505-4537 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
68001-0550-41 68001-0550 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 7, 2022 In Use
68001-0551-41 68001-0551 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 7, 2022 In Use
68001-0552-41 68001-0552 Pemetrexed disodium Pemetrexed 850.0 mg/34mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 7, 2022 In Use
68001-0553-41 68001-0553 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 7, 2022 In Use
70518-3512-00 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 7, 2022 In Use

Found 10,000 results in 5 milliseconds — Export these results